AU2021226570A1 - Cancer treatment methods - Google Patents
Cancer treatment methods Download PDFInfo
- Publication number
- AU2021226570A1 AU2021226570A1 AU2021226570A AU2021226570A AU2021226570A1 AU 2021226570 A1 AU2021226570 A1 AU 2021226570A1 AU 2021226570 A AU2021226570 A AU 2021226570A AU 2021226570 A AU2021226570 A AU 2021226570A AU 2021226570 A1 AU2021226570 A1 AU 2021226570A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- amino acid
- acid sequence
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981355P | 2020-02-25 | 2020-02-25 | |
| US62/981,355 | 2020-02-25 | ||
| US202063105104P | 2020-10-23 | 2020-10-23 | |
| US63/105,104 | 2020-10-23 | ||
| PCT/US2021/019667 WO2021173832A1 (en) | 2020-02-25 | 2021-02-25 | Cancer treatment methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021226570A1 true AU2021226570A1 (en) | 2022-09-29 |
Family
ID=75143716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021226570A Abandoned AU2021226570A1 (en) | 2020-02-25 | 2021-02-25 | Cancer treatment methods |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230165968A1 (https=) |
| EP (1) | EP4110403A1 (https=) |
| JP (1) | JP2023519807A (https=) |
| KR (1) | KR20220145871A (https=) |
| AU (1) | AU2021226570A1 (https=) |
| CA (1) | CA3169117A1 (https=) |
| WO (1) | WO2021173832A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2024130003A1 (en) | 2022-12-15 | 2024-06-20 | Bolt Biotherapeutics, Inc. | Cancer combination treatment method |
| CA3221817A1 (en) * | 2023-06-30 | 2025-06-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Combination therapies for the treatment of cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| WO2007038720A2 (en) * | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| WO2017087280A1 (en) * | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| KR20180134347A (ko) * | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| CN109843327B (zh) * | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| US20180271996A1 (en) * | 2017-02-28 | 2018-09-27 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| CA3100544A1 (en) * | 2018-05-17 | 2019-11-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates |
| US20220152215A1 (en) * | 2019-03-15 | 2022-05-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting CEA |
| US20220143012A1 (en) * | 2019-03-15 | 2022-05-12 | Bolt Biotherapeutics, Inc. | Macromolecule-Supported TLR Agonists |
| WO2020190725A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| US20220226491A1 (en) * | 2019-03-15 | 2022-07-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting PD-L1 |
| WO2020190731A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
-
2021
- 2021-02-25 CA CA3169117A patent/CA3169117A1/en active Pending
- 2021-02-25 KR KR1020227032892A patent/KR20220145871A/ko active Pending
- 2021-02-25 EP EP21713788.4A patent/EP4110403A1/en not_active Withdrawn
- 2021-02-25 US US17/802,392 patent/US20230165968A1/en not_active Abandoned
- 2021-02-25 JP JP2022550848A patent/JP2023519807A/ja active Pending
- 2021-02-25 AU AU2021226570A patent/AU2021226570A1/en not_active Abandoned
- 2021-02-25 WO PCT/US2021/019667 patent/WO2021173832A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20230165968A1 (en) | 2023-06-01 |
| CA3169117A1 (en) | 2021-09-02 |
| JP2023519807A (ja) | 2023-05-15 |
| KR20220145871A (ko) | 2022-10-31 |
| EP4110403A1 (en) | 2023-01-04 |
| WO2021173832A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114502592B (zh) | 靶向cldn18.2的抗体及其制备方法和应用 | |
| US20230165968A1 (en) | Cancer treatment methods | |
| US11400164B2 (en) | Immunoconjugates targeting HER2 | |
| TWI870335B (zh) | 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用 | |
| JP7102670B2 (ja) | 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合 | |
| EP4273170A1 (en) | Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use | |
| EP3889172A1 (en) | Targeted tgf beta inhibition | |
| KR20200016899A (ko) | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 | |
| KR20190072626A (ko) | 활성화가능한 항-ctla-4 항체 및 그의 용도 | |
| WO2018058001A1 (en) | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof | |
| KR102608723B1 (ko) | 항―ｐｄ－１ 항체 및 그의 용도 | |
| US11680102B2 (en) | Anti-BAFF receptor antibodies and uses thereof | |
| AU2021232158A1 (en) | Anti-CD36 antibodies and their use to treat cancer | |
| KR20200088810A (ko) | 항―ｏｘ４０ 항체 및 그의 용도 | |
| CN115397859A (zh) | 治疗癌症和癌症转移的联合疗法 | |
| CN117355331A (zh) | 抗Siglec组合物及其用途 | |
| CN118488964A (zh) | 抗cd36抗体及其治疗癌症的用途 | |
| WO2024130003A1 (en) | Cancer combination treatment method | |
| US20260115307A1 (en) | Anti-fucosyl-gm1 antibody drug conjugates | |
| CN112423778A (zh) | 利用免疫毒素和检查点抑制剂组合的新辅助癌症治疗 | |
| EP4725969A1 (en) | Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof | |
| HK40100877A (en) | Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use | |
| WO2025038492A1 (en) | Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof | |
| TW202440158A (zh) | 治療癌症患者之pd-1拮抗劑、lag3拮抗劑及結合191p4d12蛋白之抗體藥物結合物之組合療法 | |
| KR20210093270A (ko) | 인간화 항-SIRPα 항체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |